Concentrations of MDPV in rat striatum correlate with the psychostimulant effect

Journal of Psychopharmacology

Volumn 29, Issue 11, 2015, Pages 1209-1218

  Novellas, Judith ^a   López Arnau, Raúl ^a   Carbó, Marcel Li ^b   Pubill, David ^a   Camarasa, Jorge ^a   Escubedo, Elena ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

kinetics; MDPV; psychostimulant; rat; striatum

Indexed keywords

3,4 METHYLENEDIOXYPYROVALERONE; 4 HYDROXY 3 METHOXYPIROVALERONE; BETA GLUCURONIDASE; CATHINONE; DOPAMINE; HALOPERIDOL; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; 3,4-METHYLENEDIOXYPYROVALERONE; CENTRAL STIMULANT AGENT; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; BRAIN LEVEL; CORPUS STRIATUM; ELIMINATION HALF-LIFE; HYDROLYSIS; IN VIVO STUDY; LOCOMOTION; MALE; METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT; REARING; STEREOTYPY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DOSE RESPONSE; DRUG EFFECTS; HALF LIFE TIME; MOTOR ACTIVITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BENZODIOXOLES; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HALOPERIDOL; INJECTIONS, SUBCUTANEOUS; MALE; MOTOR ACTIVITY; PYRROLIDINES; RATS; STEREOTYPED BEHAVIOR;

EID: 84945948905     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881115598415     Document Type: Article

References (36)

1. Aarde SM, Huang PK, Creehan KM, et al. (2013) The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: Self-administration and locomotor activity in rats. Neuropharmacology 71: 130-140.
2. Anizan S, Concheiro M, Lehner KR, et al. (2014a) Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: Relationship to pharmacodynamic effects. Addict Biol. DOI: 10.1111/adb.12201 [Epub ahead of print].
3. Anizan S, Ellefsen K, Concheiro M, et al. (2014b) 3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry. Anal Chim Acta 827: 54-63.
4. Baumann MH, Partilla JS, Lehner KR, et al. (2013) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive bath salts products. Neuropsychopharmacology 38: 552-562.
5. Brunt TM, Poortman A, Niesink RJM, et al. (2011) Instability of the ecstasy market and a new kid on the block: Mephedrone. J Psychopharmacol 25: 1543-1547.
6. Cameron KN, Kolanos R, Solis E, et al. (2013) Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. Br J Pharmacol 168: 1750-1757.
7. Csák R, Demetrovics Z, Rácz J, (2013) Transition to injecting 3,4-methylene-dioxy-pyrovalerone (MDPV) among needle exchange program participants in Hungary. J Psychopharmacol 27: 559-563.
8. Dargan PI, Sedefov R, Gallegos A, et al. (2011) The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test Anal 3: 454-463.
9. Dayneka NL, Garg V, Jusko WJ, (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21: 457-478.
10. Easton N, Fry J, O'Shea E, et al. (2003) Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy). Brain Res 987: 144-154.
11. Eshleman AJ, Wolfrum KM, Hatfield MG, et al. (2013) Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85: 1803-1815.
12. European Monitoring Centre for Drug and Drug Addiction, 2014. EMCDDA-Europol Joint Report on a new psychoactive substance: MDPV (3,4-methylenedioxypyrovalerone). Available at: http://www.emcdda.europa.eu/publications/joint-report/MDPV (. accessed 20 February 2015).
13. Fantegrossi WE, Gannon BM, Zimmerman SM, et al. (2013) In vivo effects of abused bath salt constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: Drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology 38: 563-573.
14. Griffiths P, Lopez D, Sedefov R, et al. (2010) Khat use and monitoring drug use in Europe: The current situation and issues for the future. J Ethnopharmacol 132: 578-583.
15. Hamida SB, Tracqui A, de Vasconcelos AP, et al. (2009) Ethanol increases the distribution of MDMA to the rat brain: possible implications in the ethanol-induced potentiation of the psychostimulant effects of MDMA. Int J Neuropsychopharmacol 12: 749-759.
16. Haorah J, Knipe B, Gorantla S, et al. (2007) Alcohol-induced blood-brain barrier dysfunction is mediated via inositol 1,4,5-triphosphate receptor (IP3R)-gated intracellular calcium release. J Neurochem 100: 324-336.
17. King HE, Wetzell B, Rice KC, et al. (2015) An assessment of MDPV-induced place preference in adult Sprague-Dawley rats. Drug Alcohol Depend 146: 116-119.
18. Kuczenski R, Segal DS, Aizenstein ML, (1991) Amphetamine, cocaine, and fencamfamine: Relationship between locomotor and stereotypy response profiles and caudate and accumbens dopamine dynamics. J Neurosci 11: 2703-2712.
19. López-Arnau R, Martínez-Clemente J, Carbó M, et al. (2013) An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as bath salts. . Prog Neuropsychopharmacol Biol Psychiatr 45: 64-72.
20. Mandema JW, Tuk B, van Steveninck AL, et al. (1992) Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 51: 715-728.
21. Martins T, Baptista S, Gonçalves J, et al. (2011) Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: Role of tight junction proteins and matrix metalloproteinase-9. Brain Res 1411: 28-40.
22. Meltzer PC, Butler D, Deschamps JR, et al. (2006) 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogs. A promising class of monoamine uptake inhibitors. J Med Chem 49: 1420-1432.
23. Meyer MR, Du P, Schuster F, et al. (2010) Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J Mass Spectrom 45: 1426-1442.
24. Pizarro N, de la Torre R, Joglar J, et al. (2008) Serotonergic neurotoxic thioether metabolites of 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy ): Synthesis, isolation, and characterization of diastereoisomers. Chem Res Toxicol 21: 2272-2279.
25. Ramirez SH, Potula R, Fan S, et al. (2009) Methamphetamine disrupts blood-brain barrier function by induction of oxidative stress in brain endothelial cells. J Cereb Blood Flow Metab 29: 1933-1945.
26. Reagan-Shaw S, Nihal M, Ahmad N, (2008) Dose translation from animal to human studies revisited. FASEB J 22: 659-661.
27. Simmler LD, Buser TA, Donzelli M, et al. (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168: 458-470.
28. Sørensen LK, (2011) Determination of cathinones and related ephedrines in forensic whole-blood samples by liquid-chromatography-electrospray tandem mass spectrometry. J Chromatogr B 879: 727-736.
29. Troendle MM, Stromberg PE, Rose SR, (2013) Survival despite severe hyperthermia and multi-organ system dysfunction following week-long use of an MDPV containing stain remover . Clin Toxicol 51: 679-680.
30. Uralets V, Rana S, Morgan S, et al. (2014) Testing for designer stimulants: Metabolic profiles of 16 synthetic cathinones excreted free in human urine. J Anal Toxicol 38: 233-241.
31. Vardakou I, Pistos C, Spiliopoulou C, (2011). Drugs for youth via Internet and the example of mephedrone. Toxicol Lett 201: 191-195.
32. Watterson LR, Kufahl PR, Nemirovsky NE, et al. (2014) Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict Biol 19: 165-174.
33. Watterson LR, Olive MF, (2014) Synthetic cathinones and their rewarding and reinforcing effects in rodents. Adv Neurosci (Hindawi) 2014: 209875.
34. Winstock A, Mitcheson L, Ramsey J, et al. (2011) Mephedrone: Use, subjective effects and health risks. Addict Abingdon Engl 106: 1991-1996.
35. Wright TH, Cline-Parhamovich K, Lajoie D, et al. (2013) Deaths involving methylenedioxypyrovalerone (MDPV) in Upper East Tennessee. J Forensic Sci 58: 1558-1562.
36. Wyman JF, Lavins ES, Engelhart D, et al. (2013) Postmortem tissue distribution of MDPV following lethal intoxication by bath salts. . J Anal Toxicol 37: 182-185.